BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (âInhibikaseâ or âCompanyâ), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (âPAHâ), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments.
Related Questions
What is the revenue growth rate compared to the previous quarter and yearâoverâyear, and what does it indicate about the company's momentum?
How does Inhibikase's cash runway compare to its projected R&D expenses for its PAH programs?
Are there any updates on clinical trial milestones or enrollment progress for the company's lead PAH candidate?
Did the company announce new partnerships, licensing agreements, or collaborations that could impact future cash flows or strategic positioning?
How do Inhibikase's operating expenses and SG&A costs compare to other midâstage biotech peers focused on pulmonary arterial hypertension?
What guidance did management provide for Q3 2025 and the fullâyear 2025 outlook, including revenue and expense forecasts?
What is the expected dilution impact from any recent equity raises, convertible securities, or stock option exercises?
How does the sentiment score of 30 align with analyst sentiment and market expectations for IKT, and could it signal a potential price swing?
What macroeconomic or sector trends (e.g., interest rates, healthcare policy changes) might amplify or dampen the market reaction to this earnings release?
Are there any regulatory or compliance updatesâsuch as FDA filings or IND submissionsâthat could affect the timeline for product commercialization?
How will the reported Q2 2025 earnings affect Inhibikase Therapeutics' stock valuation in the short term?